Drug evaluation: Degarelix--a potential new therapy for prostate cancer.
Ferring Research Ltd and licensee Astellas Pharma Inc are developing the gonadotropin-releasing hormone antagonist degarelix as a potential subcutaneous treatment for prostate cancer.